Furer V, Eviatar T, Zisman D, et al. - This study was intended to examine immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population. Researchers designed a multicentre observational study to evaluate the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with autoimmune inflammatory rheumatic diseases (n=686) compared with the general population (n=121). They investigated serum IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins 2–6 weeks after the second vaccine dose. The findings reveal that in the majority of patients with autoimmune inflammatory rheumatic diseases, mRNA BNTb262 vaccine was immunogenic, with an acceptable safety profile. It was shown that treatment with glucocorticoids, rituximab, MMF, and abatacept was correlated with a significantly reduced BNT162b2-induced immunogenicity.